Low forms of cyclin E reduce breast cancer drug's effectiveness
Tuesday, February 9, 2010 - 14:21
in Health & Medicine
Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers report.
Read the whole article on Science Daily
More from Science Daily
Related
- Low forms of cyclin E reduce breast cancer drug's effectivenessTue, 9 Feb 2010, 13:58:50 EST
- Anti-estrogen drug therapy reduces risk of invasive breast cancer in older womenTue, 10 Jun 2008, 21:49:44 EDT
- Meta-analyses of global trials finds in favor of aromatase inhibitorsThu, 11 Dec 2008, 16:57:26 EST
- Raloxifene reduces risk of invasive estrogen-receptor positive breast cancerTue, 10 Jun 2008, 21:49:51 EDT
- Exemestane may be another first-line, adjuvant therapy for hormone-receptor positive, early-stage breast cancerThu, 9 Dec 2010, 10:38:40 EST